ClearPoint Neuro (CLPT) Stock Analysis & Winston Score

ClearPoint Neuro makes medical devices and software that help surgeons perform precise procedures inside the brain. Its main product is a navigation system that works inside MRI machines, allowing doctors to guide tiny instruments to exact locations in the brain with high accuracy. The company serves hospitals, academic medical centers, and pharmaceutical companies running clinical trials for brain-related therapies. ClearPoint makes money through a mix of product sales, disposable device kits used in each procedure, and service agreements. It operates primarily in the United States, with a small international presence, and generates around $30–35 million in annual revenue. Its competitive edge comes from being one of the few platforms designed specifically for MRI-guided neurosurgery, which creates a specialized niche that is hard to replicate. The biggest growth driver is the expanding field of gene therapy and drug delivery directly into the brain, where ClearPoint's platform is used in many clinical trials — though the company currently runs at a significant operating loss, making profitability the central risk to watch.